Update on the management of asthma

Advances in Internal Medicine

Volumn 46, Issue , 2001, Pages 31-50

  Prussin, Caiman ^a   Metcalfe, Dean D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; CORTICOSTEROID;

ADOLESCENT; ADULT; ASTHMA; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; FEMALE; HOSPITALIZATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PRESCHOOL CHILD; PROGNOSIS; REVIEW;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 0035219322     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Mannino DM, Homa DM, Pertowski ÇA, et al: Surveillance for asthma-United States, 1960-1995. MOT Mortal Wkly Rep CDC Surveill Summ 47:1-27, 1998.
2. Platts-Mills TA: Asthma among inner city children. Pediatr Pulmonol 24:231-233, 1997.
3. National Asthma Education and Prevention Program (National Heart Lung and Blood Institute) Second Expert Panel on the Management of Asthma. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health, National Heart Lung and Blood Institute, 1997.
4. Bochner BS, Undem BJ, Lichtenstein LM: Immunological aspects of allergic asthma. Annu Rev Immunol 12:295-335, 1994.
5. Wills-Karp M: Immunologie basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 17:255-281, 1999.
6. Hartert TV, Windom HH, Peebles RS, Jr, et al: Inadequate outpatient medical therapy for patients with asthma admitted to two urban hospitals. AmJMed 100:386-394, 1996.
7. Legorreta AP, Christian-Herman J, O'Connor RD, et al: Compliance with national asthma management guidelines and specialty care: A health maintenance organization experience. Arch Intern Med 158:457-464, 1998.
8. Leidy KN, Chan KS, Coughlin C: Is the asthma quality of life questionnaire a useful measure for low-income asthmatics? Am J Respir Crit Care Med 158:1082-1090, 1998.
9. Kikuchi Y, Okabe S, Tamura G, et al: Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl JMed 330:1329-1334, 1994.
10. Kendrick AH, Higgs CM, Whitfield MJ, et al: Accuracy of perception of severity of asthma: Patients treated in general practice. BMJ 307:422-424, 1993.
11. Boushey HA: Effects of inhaled corticosteroids on the consequences of asthma/ J Allergy Clin Immunol 102:S5-S16, 1998.
12. Pauwels RA, Lofdahl CG, Postma DS, et al: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. NEnglJMed 337:1405-1411, 1997.
13. Donahue JG, Weiss ST, Livingston JM, et al: Inhaled steroids and the risk of hospitalization for asthma. JAMA 277:887-891, 1997.
14. Haahtela T, Jarvinen M, Kava T, et al: Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 331:700-705, 1994.
15. Agertoft L, Pedersen S: Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. RespirMed 88:373-381, 1994.
16. Kelly HW: Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 102:836-851, 1998.
17. Szefler SJ, Boushey HA, Pearlman DS, et al: Time to onset of effect of fluticasone propionate in patients with asthma/ J Allergy Clin Immunol 103:780-788, 1999.
18. Sorkness CA: Establishing a therapeutic index for the inhaled corticosteroids: Part II. Comparisons of systemic activity and safety among different inhaled corticosteroids/ J Allergy Clin Immunol 102:852864, 1998.
19. Verberne AA, Frost C, Roorda RJ, et al: One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Grit Care Med 156:688-695, 1997.
20. Tinkelman DG, Reed CE, Nelson HS, et al: Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children [see comments]. Pediatrics 92:64-77, 1993.
21. Simons FE: A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone DipropionateSalmeterol Xinafoate Study Group. N Engl J Med 337:1659-1665, 1997.
22. Alien DB, Bronsky EA, LaForce CF, et al: Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group/ J Pediatr 132:472-477, 1998.
23. Price JF, Russell G, Hindmarsh PC, et al: Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol 24:178-186, 1997.
24. Gumming RG, Mitchell P, Leeder SR: Use of inhaled corticosteroids and the risk of cataracts. NEnglJMed 337:8-14, 1997.
25. Garbe E, Suissa S, LeLorier J: Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 280:539-543,1998.
26. Smith LJ, Geller S, Ebright L, et al: Inhibition of leukotriene D4induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am Rev Respir Dis 141:988-992, 1990.
27. Drazen J: Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. .Am J Respir Crit Care Med 157:8233S237, 1998; discussion S47-S48.
28. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al: Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 130:487-495, 1999.
29. Drazen JM, Israel E: Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Yes. Am J Respir Crit Care Med 158:1697-1698, 1998.
30. Israel E, Cohn J, Dube L, et al: Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 275:931-936, 1996.
31. Bennett JA, Smyth ET, Pavord ID, et al: Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 49:771-774,1994.
32. van Noord JA, Smeets JJ, Raaijmakers JA, et al: Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action. Eur Respir f 9:1684-1688, 1996.
33. Szefler SJ, Nelson HS: Alternative agents for anti-inflammatory treatment of asthma, f Allergy Clin Immunol 102:823-835,1998.
34. Nelson HS, Busse WW, deBoisblanc BP, et al: Fluticasone propionate powder: Oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol 103:267-275, 1999.
35. Noonan M, Chervinsky P, Busse WW, et al: Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 152:1467-1473,1995.
36. MacGlashan DW Jr, Bochner BS, Adelman DC, et al: Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody/ J Immunol 158:14381445, 1997.
37. Fahy JV, Fleming HE, Wong HH, et al: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155:18281834, 1997.
38. Boulet LP, Chapman KR, Cote J, et al: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155:1835-1840, 1997.
39. Fahy JV, Cockcroft DW, Boulet LP, et al: Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 160:1023-1027,1999.
40. Borish L, Nelson HS, Bensch G, et al: Phase I/II study of soluble interleukin-4 receptor in adult patients with moderate asthma. Proceedings of the European Respiratory Society Annual Conference 1999; abstract P1983.
41. Kon OM, Sihra BS, Compton CH, et al: Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 352:1109-1113, 1998.